News about University Research Park tenants.
If you have a news article or announcement you'd like considered for our news room, please e-mail a copy of the article to firstname.lastname@example.org.
November 17, 2013
Cary, NC - November 17, 2013. BMG LABTECH, Inc. - the Microplate Reader Company - and InvivoSciences, Inc. - a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery - announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The ultra- sensitive plate reader, CLARIOstar®, will analyze rapid beat-to-beat changes (up to 50 Hz) in the fluorescence intensities of dyes that indicate physiological states in engineered 3D heart tissue after drug/compound application.
November 16, 2013
In 2008, before tech accelerator programs exploded onto the scene, a couple of successful Madison entrepreneurs had a smaller idea: To form a group that would give one-on-one help to people with a promising concept but little knowledge how to turn it into a real business.
With backing from UW-Madison, Terry Sivesind and Toni Sikes created MERLIN (Madison Entrepreneur Resource, Learning and Innovation Network) Mentors.
October 24, 2013
After Tony Kolton sold his software company -- Logical Information Machines – in 2009, he sailed in the Caribbean and enjoyed other recreational pursuits.
But it didn’t take the 59-year-old Kolton long to grow bored.
With an interest in biotechnology, he turned his attention to the potential of stem cell therapies and founded Regenerative Medical Solutions in January of 2012. The startup, based at University Research Park in Madison, is working to help cure diabetes.
August 5, 2013
NCD Technologies, a rising star in nano technologies, is proud to announce that their Nanocrystalline Diamond Pretreatment (NDP) an innovative and unprecedented process for applying diamond coatings to extremely small tooling, has been selected by R&D Magazine’s 100 list for technological excellence.
August 1, 2013
For Advanced Development of StrataGraft® Skin Tissue for Thermal Burns
Stratatech Corp has been awarded a contract valued at up to $47.2 M by the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA). The contract is for the advanced clinical and manufacturing development of StrataGraft® skin tissue, its skin replacement product, as a medical countermeasure to treat patients with severe thermal burns.
July 31, 2013
Madison, WI-based Stratatech has won up to $47.2 million from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to advance clinical manufacturing and development of its StrataGraft® skin tissue to treat patients with severe thermal burns.
July 29, 2013
Arecor Ltd of Cambridge, England received the “green light” and funding to pursue a research project applying Arecor’s innovative Arestat™ formulation technology to a promising flu vaccine, REDEE FLU™, developed by FluGen, Inc., of Madison, WI. The UK’s innovation agency, the Technology Strategy Board, has awarded Arecor a Proof of Concept award through its Smart programme, to engage in research and development in the strategically important area of developing a stable formulation for REDEE FLU™.
July 11, 2013
A new kind of bird flu that has killed 43 people in China shows potential in the lab for sparking a global outbreak, according to a study by UW-Madison researcher Yoshihiro Kawaoka.
Kawaoka did the altered H5N1 work at UW-Madison’s Institute for Influenza Virus Research at University Research Park. The lab is classified as Biosafety Level 3-Agriculture, the highest biosafety level at the university and half a notch below the top level anywhere of BSL4.
June 4, 2013
Cellular Dynamics International, created by UW-Madison stem cell pioneer James Thomson in 2004, plans to sell its stock on the public market, the first Madison company to go public in six years.
March 28, 2013
Primorigen Biosciences, Madison, has received a $1.2 million Phase 2 Small Business Innovation Research grant from the National Institutes of Health.
The funds will speed the company’s work on a new, cost-effective system for producing stem cells and transforming them into specific cell lines, such as blood, liver and neural cells, said chief executive Chuck Oehler. Primorigen will collaborate on the project with EMD Millipore Corp., a division of Merck.
January 16, 2013
Stratatech Corp., a leader in regenerative medicine, today announced top-line results from its proof-of-concept clinical trial of StrataGraft®, a universal human skin substitute being developed for the treatment of severe burns.